Hinge Health is projected to report Q3 2026 revenue of $224.78 million (+45.8% YoY) and EPS of $0.58, with its current stock price of $116.90 trading slightly above the average analyst price target of $114.31.
Investors are primarily focused on the integration of the recent Cylinder Health acquisition and the company’s strategic expansion into gastrointestinal (GI) and migraine care as it transitions toward a multi-product platform.
Following a strong second quarter where revenue surged 53%, management raised its full-year 2026 revenue guidance to a midpoint of $858 million. Analysts will be closely monitoring LTM calculated billings and the impact of integration costs on the company's improved operating leverage and 28% non-GAAP margin target.